Longeveron (LGVN) Other Non-Current Liabilities (2024 - 2025)
Longeveron (LGVN) recorded quarterly Other Non-Current Liabilities of $330000.0 in Q4 2025, up 4.76% quarter-over-quarter from $315000.0 in Q3 2025, and up 24.53% on a YoY basis from $265000.0 in Q4 2024.
Longeveron (LGVN) Other Non-Current Liabilities (2024 - 2025) Analysis & Trends
Longeveron's Other Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $330000.0 for Q4 2025.
- In Q4 2025, Other Non-Current Liabilities rose 24.53% year-over-year to $330000.0; the TTM figure through Dec 2025 stood at $330000.0 (up 24.53% YoY), while the FY2025 annual figure was $330000.0, up 24.53% from the prior year.
- Other Non-Current Liabilities was $330000.0 for Q4 2025 at Longeveron, up from $315000.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $330000.0 in Q4 2025 to a low of $66000.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Longeveron | 20.35 Bn | 20.33 Bn | 264,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 330,000.00 |
| Sep 30, 2025 | 315,000.00 |
| Jun 30, 2025 | 308,000.00 |
| Mar 31, 2025 | 302,000.00 |
| Dec 31, 2024 | 265,000.00 |
| Sep 30, 2024 | 199,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Mar 31, 2024 | 66,000.00 |